3
REGN
REGENERON PHARMACEUTICALS · Health Care
Consensus score 3/100 · #140 this quarter · tier-weighted across tracked managers
→NeutralPrice action since filingas of 2026-09-30
vs 50-day avg
+2.8%
21-day momentum
-9.0%
recent volume
0.78×
13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.
S3· ToppingStage Analysis · Weinstein
vs 30-wk avg
+0.8%
30-wk MA slope
+1.4%
rel. strength
-15.4
52-wk range
68%
Topping — momentum stalling at the highs; distribution risk. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.
Holders
2
tracked managers
New this Q
0
opened a position
Avg weight
2.5%
of their portfolios
Combined value
$95M
held, at quarter-end
Who’s holding it Q2 2026, by position size
| Manager | Position size | Value | Change |
|---|---|---|---|
| Southeastern / Longleaf Deep value | 5.0% | $95M | ADD |
| Horizon Kinetics Franchise/inflation | 0.0% | $402K | TRIM |
Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.